The class I innovative drug NIP046 developed by CR Pharmaceutical was approved for clinical trial targeting rheumatoid arthritis indications.
The class I innovative drug NIP292 obtained the Orphan Drug Designation (ODD) issued by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).
CR Double-Crane acquired 38.75% of the stake of Dongying Tiandong Pharmaceutical Co., Ltd.